DelveInsight’s, “Ewing’s Sarcoma – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Ewing’s Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Ewing’s Sarcoma Understanding
Ewing’s Sarcoma: Overview
Ewing's sarcoma is a cancerous (malignant) tumor that usually begins growing in a bone. It occurs primarily in children and young adults, often appearing during the teen years. There is no known cause of Ewing's sarcoma. Symptoms of Ewing’s sarcoma includes: pain, swelling, or stiffness in the area of the tumor (arms, legs, chest, back, or pelvis) for weeks or months. Physical exam, X-ray, Bone scan, CT scan, MRI are most used diagnostic procedures for Ewing sarcoma. The main treatments for ewing sarcoma are chemotherapy, surgery, and radiation. These treatments are often used in some combination with each other.

"Ewing’s Sarcoma - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ewing’s Sarcoma pipeline landscape is provided which includes the disease overview and Ewing’s Sarcoma treatment guidelines. The assessment part of the report embraces, in depth Ewing’s Sarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ewing’s Sarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
● The companies and academics are working to assess challenges and seek opportunities that could influence Ewing’s Sarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Ewing’s Sarcoma.

Ewing’s Sarcoma Emerging Drugs Chapters
This segment of the Ewing’s Sarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ewing’s Sarcoma Emerging Drugs
● Vigil immunotherapy: Gradalis, Inc.
Phase III clinical trials are being conducted by gradalis, Inc. for Intradermal autologous Vigil immunotherapy in combination with irinotecan and temozolomide in subjects with metastatic Ewing's sarcoma Family of Tumors (ESFT).

● Eribulin mesylate: Eisai, Inc.
Eribulin Mesylate is the mesylate salt of a synthetic analogue of halichondrin B, a substance with antineoplastic activity. Eribulin mesylate clinical trials are going on in phase II stage of development by eisai, Inc for Ewing sarcoma.
Further product details are provided in the report……..

Ewing’s Sarcoma: Therapeutic Assessment
This segment of the report provides insights about the different Ewing’s Sarcoma drugs segregated based on following parameters that define the scope of the report, such as:
● Major Players in Ewing’s Sarcoma
There are approx. 10+ key companies which are developing the therapies for Ewing’s Sarcoma. The companies which have their Ewing’s Sarcoma drug candidates in the most advanced stage, i.e. phase III include,Gradalis, Inc.
● Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

● Route of Administration
Ewing’s Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Subcutaneous
• Intravenous
• Intramuscular

● Molecule Type
Products have been categorized under various Molecule types such as
• Bispecific Antibody
• Peptides
• Small molecule
• Gene therapy
● Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ewing’s Sarcoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ewing’s Sarcoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ewing’s Sarcoma drugs.

Ewing’s Sarcoma Report Insights
• Ewing’s Sarcoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Ewing’s Sarcoma Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Ewing’s Sarcoma drugs?
• How many Ewing’s Sarcoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ewing’s Sarcoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ewing’s Sarcoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ewing’s Sarcoma and their status?
• What are the key designations that have been granted to the emerging drugs?